Genprex pinpoints key biomarkers to predict Reqorsa gene therapy success at ASCO
Genprex (NASDAQ:GNPX) announced the official abstract publication of positive clinical biomarker data for its lead oncology candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.








-640x360.webp&w=3840&q=75)

